Stock ASND ASCENDIS PHARMA A/S
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : Ascendis Pharma A/S

Company Ascendis Pharma A/S

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2023-11-30 pm EST 		Intraday chart for Ascendis Pharma A/S 5-day change 1st Jan Change
100.43 USD +3.46% +7.99% -17.77%
Nov. 30 European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
Nov. 29 European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher Wednesday MT

Business Summary

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Number of employees : 797

Sales per Business

USD in Million2021Weight2022Weight Delta
Pharmaceutical Products
100.0 %
9 100.0 % 54 100.0 % +485.01%

Sales per region

USD in Million2021Weight2022Weight Delta
North America
86.3 %
8 88.1 % 46 86.3 % +472.66%
China
12.6 %
1 11.9 % 7 12.6 % +523.57%
Europe
1.1 %
-- 1 1.1 % -

Managers

Managers TitleAgeSince
Jan Mikkelsen FOU
 Founder 64 2006
Scott Smith DFI
 Director of Finance/CFO 49 2016
Stina Singel CTO
 Chief Tech/Sci/R&D Officer 49 2021
Kennett Sprogøe CTO
 Chief Tech/Sci/R&D Officer 45 2007
Birgitte Volck CTO
 Chief Tech/Sci/R&D Officer 60 2016
Lotte Sønderbjerg ADM
 Chief Administrative Officer 61 2007
Sigurd Okkels PRN
 Corporate Officer/Principal - 2019
Peter Rasmussen AUD
 Comptroller/Controller/Auditor 54 2014
Flemming Steen Jensen PRN
 Corporate Officer/Principal 62 2015
Michael Wolff Jensen LAW
 General Counsel 52 2007

Members of the board

Members of the board TitleAgeSince
Jan Mikkelsen FOU
 Founder 64 2006
Albert Cha CHM
 Chairman 50 2014
Rafaèle Elisabeth Tordjman CHM
 Chairman 53 2007
Michael Wolff Jensen LAW
 General Counsel 52 2007
Birgitte Volck CTO
 Chief Tech/Sci/R&D Officer 60 2016
Lisa Bright BRD
 Director/Board Member 55 2017
Lars Holtug BRD
 Director/Board Member 65 2018
William C. Fairey BRD
 Director/Board Member 58 2022

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 57,656,568 6,000,000 ( 10.41 %) 0 10.41 %

Shareholders

NameEquities%Valuation
RA Capital Management LP
18.76 %
10,719,555 18.76 % 957 M $
Fidelity Management & Research Co. LLC
8.291 %
4,738,392 8.291 % 423 M $
Avoro Capital Advisor LLC
6.421 %
3,670,000 6.421 % 328 M $
Janus Henderson Investors US LLC
5.574 %
3,185,771 5.574 % 285 M $
T. Rowe Price Investment Management, Inc.
5.447 %
3,113,258 5.447 % 278 M $
Artisan Partners LP
4.550 %
2,600,460 4.550 % 232 M $
Capital Research & Management Co. (International Investors)
3.794 %
2,168,443 3.794 % 194 M $
Massachusetts Financial Services Co.
2.357 %
1,346,819 2.357 % 120 M $
Franklin Advisers, Inc.
2.082 %
1,190,175 2.082 % 106 M $
Capital Research & Management Co. (Global Investors)
1.862 %
1,063,909 1.862 % 95 M $
NameEquities%Valuation
Wellington Management Co. LLP
4.360 %
2,073,159 4.360 % 185 M $
T. Rowe Price Associates, Inc. (Investment Management)
3.202 %
1,522,356 3.202 % 136 M $
Jan Mikkelsen
0.6914 %
328,716 0.6914 % 29 M $
Russell Investment Management LLC
0.0155 %
7,374 0.0155 % 658 572 $
Fideuram Asset Management (Ireland) DAC
0.009982 %
4,746 0.009982 % 423 865 $
Scott Smith
0.005374 %
2,555 0.005374 % 228 187 $
Vibeke Miller Breinholt
0.004053 %
1,927 0.004053 % 172 100 $
Stina Singel
0.002665 %
1,267 0.002665 % 113 156 $
Flemming Steen Jensen
0.001950 %
927 0.001950 % 82 790 $
Lotte Sønderbjerg
0.001950 %
927 0.001950 % 82 790 $

Company contact information

Ascendis Pharma A/S

Tuborg Boulevard 12

2900, Hellerup

+45 70 22 22 44

http://www.ascendispharma.com
address Ascendis Pharma A/S(ASND)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Ascendis Pharma A/S

Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
92.08EUR
Average target price
131.27EUR
Spread / Average Target
+42.55%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ASCENDIS PHARMA A/S Stock Ascendis Pharma A/S
-17.77% 5 679 M $
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+22.87% 91 429 M $
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+14.18% 87 610 M $
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
+1.98% 34 419 M $
ARGENX SE Stock argenx SE
+16.97% 26 250 M $
BIONTECH SE Stock BioNTech SE
-33.16% 23 869 M $
GENMAB A/S Stock Genmab A/S
-26.52% 20 655 M $
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.00% 19 460 M $
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
-2.42% 11 455 M $
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
+21.83% 11 056 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock Ascendis Pharma A/S - Nasdaq
  4. Company Ascendis Pharma A/S
As early as today, start finding the best investment opportunities!
Optimize my profits
fermer